N-methyl-D-aspartate Receptor Antagonist Drug Class List

Drugs in Drug Class: N-methyl-D-aspartate Receptor Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-004	Jul 18, 2016	AB	RX	Yes	No
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-004	Jul 18, 2016	AB	RX	Yes	No					Y
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-002	Dec 23, 2014	AB	RX	Yes	Yes
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-002	Dec 23, 2014	AB	RX	Yes	Yes					Y

Market Dynamics and Patent Landscape for N-Methyl-D-Aspartate (NMDA) Receptor Antagonist Drugs

Last updated: July 21, 2026

NMDA receptor antagonists segment revenue is shaped by (1) long-cycle originator IP around specific active ingredients and formulations, (2) opioid-sedation and dissociative safety constraints that steer labeling and payer access, (3) shrinking patent headroom for first-wave agents, and (4) rising reformulation and route-of-administration strategies to defend against generic and biosimilar substitutes. In practice, most freedom-to-operate outcomes hinge on whether a competitor targets ketamine (and its enantiomer/esketamine), dextromethorphan- or memantine-class derivatives, or NMDA-channel blockers with distinct regulatory pathways and distinct Orange Book footprints.

---

Which NMDA receptor antagonists dominate the market and why do patents matter?

Fast answer: The NMDA antagonist market is anchored by ketamine and esketamine (treatment of depression via different pathways), memantine (Alzheimer’s disease), and dextromethorphan-containing products (often targeting combination or extended-release formulations rather than pure NMDA antagonism). Patent value concentrates in: (1) brand-specific active ingredient protection, (2) device and delivery systems (for esketamine nasal), (3) method-of-use (depression regimens), and (4) formulation and manufacturing improvements that block “generic-by-another-name” copycats.

Market structure by active ingredient

Active ingredient (NMDA antagonist)	Typical indication(s)	Commercial anchor brand(s)	Patent leverage profile
Ketamine (racemate)	Depression, anesthesia, chronic pain	Generic ketamine; brand use depends on jurisdiction	Heavy off-patent pressure, but ongoing reformulation and dosing/IP varies by product line
Esketamine	Treatment-resistant depression, depressive episodes with acute suicidality risk (where approved)	Spravato	Strongest delivery-system and regimen patent estate in the class
Memantine	Moderate-to-severe Alzheimer’s disease	Namenda (and IR/ER variants)	Much of active-ingredient IP is older; product-line formulation and second-generation protections can persist
Dextromethorphan (NMDA-related)	Pseudobulbar affect, agitation, neurodegenerative symptom domains depending on product	Multiple brands and combinations	Many protections sit in controlled release and combination claims, not only NMDA antagonism

Why patent scope drives pricing and contracting

1. Originator exclusivity is route-specific. Esketamine IP is tied to intranasal delivery and specific dosing regimens. That narrows generic entry options even when the molecule is not broadly “locked.”
2. Safety labeling limits substitution. NMDA antagonists have CNS adverse effects. Payers often require step edits and insist on product-specific criteria. That can preserve brand revenue even as some competitors launch “therapeutically similar” products.
3. Patent estates shift from molecule to device/formulation. As active-ingredient patents expire, challengers face harder barriers if the remaining claims cover specific particle size, excipient system, spray parameters, or manufacturing controls.

Sources: FDA product labeling for ketamine and esketamine (Spravato), and FDA labeling for memantine and dextromethorphan-containing NMDA-relevant agents. [1–4]

---

How strong is the patent estate across the NMDA antagonist class?

Fast answer: The strongest and most actively litigated NMDA antagonist IP is in esketamine (Spravato) due to delivery-system claims and regimen method-of-use coverage. Memantine’s core active-ingredient claims are largely historical; remaining protection tends to be product-line, including extended-release variants and process/formulation claims. Ketamine faces generic saturation in many geographies, making patent defensibility mostly product-specific rather than molecule-wide. Dextromethorphan markets are frequently defended through extended-release and combination patents.

Patent estate “shape” by molecule

Molecule cluster	Claim types that matter most	Typical remaining risk windows
Esketamine	delivery system/device-like claims, method-of-use (TRD regimen), composition/formulation, manufacturing	Later-cycle, because delivery and regimen patents can outlast earlier molecule filings
Memantine	formulation (IR vs ER), process, sometimes method-of-use expansions	Earlier headroom for pure ingredient, later headroom for specific products
Ketamine	product-specific dosing/compositions where applicable, but most routes are off-patent	Low active-ingredient barrier; higher reliance on brand-only reimbursement structures
Dextromethorphan products	combinations and extended-release; NMDA-related pharmacology is often embedded in product claims	Patent risk depends on whether the competitor copies the formulation/combination and dosing interval

Sources: FDA labeling and approvals for Spravato and class-relevant NMDA antagonists. [1–4]

---

When do NMDA receptor antagonist drugs lose exclusivity in the U.S.?

Fast answer: Exclusivity timing is not uniform across the class. The decisive factor is each brand’s Orange Book patent set plus any non-patent exclusivity tied to the original approval. In practice, the class splits into: (1) established off-patent molecules (ketamine, older memantine product lines) where generic entry risk is immediate, and (2) later-expiring delivery/regimen estates (esketamine) where entry is delayed by remaining Orange Book patents and associated litigation.

Exclusivity timeline mechanics (how it is usually decided)

• Patent expiration governs statutory bar for generic approval where Orange Book-listed patents remain in force.
• 180-day exclusivity can be triggered for a first Paragraph IV filer, but the ability to launch depends on both the patent status and the presence/structure of settlement agreements.

This is the operational framework used in NMDA antagonist cases where Orange Book patents are contested through Paragraph IV challenges.

Sources: 21 U.S.C. Hatch-Waxman framework and FDA Orange Book listing practices are the governing mechanics. [5]

---

What patents protect Spravato (esketamine) and what is the Orange Book status?

Fast answer: Spravato’s defense centers on Orange Book-listed patents covering intranasal composition/formulation, delivery attributes, and treatment regimens. Orange Book status is the controlling entry gate for FDA approval of generics or “therapeutic equivalents” under Hatch-Waxman.

Orange Book status approach for NMDA antagonists

For each contender product, the relevant fields are:

• Patent number and listed expiration date
• Patent type (composition, method of use, formulation/process)
• Whether the patent has been litigated (Paragraph IV challenges)
• Whether any patent has “carved out” exclusivity through settlements

Operational guidance: use the Orange Book listing for the specific dosage form (for esketamine, intranasal devices and dosage strengths), because some patents attach to a specific product configuration rather than the active ingredient alone. [5]

Sources: FDA Orange Book structure and Hatch-Waxman mechanics. [5]

---

What generic entry risks exist for NMDA antagonist drugs after Paragraph IV challenges?

Fast answer: Generic risk concentrates where (1) Orange Book patent coverage is narrow and expires earlier, and (2) settlement agreements eliminate remaining barriers or cap damages. For the class, ketamine is broadly exposed to generic entry. Esketamine and certain dextromethorphan formulations face more structured barriers due to delivery/formulation and method-of-use coverage.

Generic launch risk matrix

Product area	Why generics can enter	Why generics can be delayed
Ketamine	active ingredient broadly accessible; multiple supply channels	label and product availability factors can still support brand-like contracting in some settings
Memantine IR/ER	older ingredient and product IP can be weak versus filing timelines	product-line formulation and process patents can delay copycats for specific strengths/forms
Esketamine intranasal	smaller number of approved competitors if patents fall	delivery/formulation and regimen method-of-use patents can require carve-outs, licensing, or design-around
Dextromethorphan combinations/ER	many NMDA-relevant claims are tied to specific release profiles and combos	product-specific formulation claims can block “generic-by-switch” if the challenger cannot match release profile and combination constraints

Sources: FDA Orange Book and Hatch-Waxman practice. [5]

---

How does esketamine compare with ketamine on patent durability and commercial dynamics?

Fast answer: Esketamine’s patent durability is structurally higher because its product platform is a specific intranasal delivery system with a dense Orange Book set and regimen claims tied to depression treatment protocols. Ketamine generally faces lower molecule-level protection and higher generic availability, making revenue more sensitive to pricing pressure and payer formulary placement.

Comparative IP and commercialization

Dimension	Esketamine (Spravato)	Ketamine (racemate products)
Delivery system	intranasal platform with product-specific claims	multiple formulations; many generic suppliers
Claim density trend	high, because route + method-of-use can both be protected	lower for molecule-only copy because ingredient is widely available
Litigation pattern	typically tied to Orange Book-listed product patents	fewer brand-generic contests around “new” patented formulations unless specific product lines are still protected
Payer sensitivity	controlled use protocols protect brand access	generic cost advantage drives formulary placement

Sources: FDA labeling for Spravato and general ketamine product labeling. [1,3]

---

Which NMDA antagonist formulations are most protected: oral, extended-release, or intranasal?

Fast answer: Formulation and delivery-system patents are most protective for intranasal esketamine and extended-release/combination dextromethorphan products. Oral IR versus ER memantine often has meaningful formulation coverage but tends to be weaker than delivery-system estates once older product-line patents lapse.

Formulation claim hotspots

1. Intranasal delivery attributes (for esketamine): composition and performance characteristics that affect spray pattern, particle delivery, and stability.
2. Extended-release profiles (for dextromethorphan products): release kinetics and excipient matrices.
3. Process and manufacturing controls: granulation or blending parameters, impurity profiles, and stability constraints that can become nontrivial under ANDA comparability requirements.

Sources: FDA product labeling for approved NMDA antagonist products and general formulation protection patterns under Orange Book practice. [1–4,5]

---

What method-of-use patents cover NMDA antagonists and how do they affect litigation?

Fast answer: Method-of-use patents are a common lever for NMDA antagonists in psychiatric indications (for example, depression treatment regimens). They can delay generic competition even when a challenger can copy the composition, because ANDA labels and “carve-out” strategies may be required to avoid infringing the claimed regimen.

Method-of-use impact on Paragraph IV strategy

• Carve-out labels can be used to omit the infringing dosage regimen, but this depends on the scope of the Orange Book-listed method-of-use claims.
• Settlement terms may include licensed launch dates, mutual covenants not to sue, or exclusivity-sharing arrangements.

Sources: Hatch-Waxman settlement and Paragraph IV strategy mechanics; Orange Book patent listing control. [5]

---

What patent litigation affects NMDA receptor antagonist drugs right now?

Fast answer: The class’s most material and recurring litigation risk concentrates around esketamine’s Orange Book patent set and any remaining late-stage patents covering formulation, delivery performance, and depression regimen method-of-use. Other molecules in the class tend to have lower active litigation intensity at the product-line level when their Orange Book estates are already expired or are less densely listed.

Sources: FDA Orange Book usage for litigation gatekeeping. [5]

---

How do settlement agreements shape NMDA antagonist market access?

Fast answer: Settlements typically determine (1) the earliest launch date for generic or “authorized” competitors, (2) labeling carve-outs, (3) whether additional patents are dismissed or remain in play, and (4) distribution or supply constraints tied to design-around attempts.

In NMDA antagonists, these terms matter most for intranasal esketamine and for combinations/extended-release products where design-around is more difficult.

Sources: Hatch-Waxman settlement framework and Orange Book controlling function. [5]

---

What is the FDA regulatory status of NMDA antagonists that drives exclusivity?

Fast answer: Regulatory status that affects exclusivity includes whether the product is under a full NDA, 505(b)(2), or abbreviated pathways. NMDA antagonist exclusivity and patent strategy differ because:

• Depression indications often use tight REMS and controlled distribution, strengthening brand continuity even when some IP falls away.
• Alzheimer’s and combination dextromethorphan segments often use older regulatory baselines where patent-driven barriers are the dominant determinant of generic entry.

Sources: FDA approvals and labeling for Spravato, memantine, ketamine, and dextromethorphan-containing products. [1–4]

---

Key drug-by-drug patent exposure map for the NMDA antagonist class

Fast answer: The following map focuses on which areas are typically most exposed to generic or “therapeutic equivalent” pressure. It is framed around the patent and Orange Book gatekeeping mechanism, which determines ANDA success.

Drug	Patent exposure direction	Primary defensibility axes
Esketamine (intranasal)	Lower near-term generic risk while Orange Book patents remain active	delivery/formulation claims, method-of-use claims, regimen-specific barriers
Memantine (IR/ER)	Moderate exposure depending on remaining product-line patents	formulation and process claims for specific ER/IR products
Ketamine	High exposure due to broad generic availability	brand relies more on contracting and product access than on molecule-level patents
Dextromethorphan products	Variable; depends on extended-release and combination claims	sustained-release profiles, combination claims, dosing interval constraints

Sources: FDA labeling and Orange Book practice. [1–5]

---

Key Takeaways

• NMDA antagonist market dynamics are driven by product-specific patent estates rather than class-wide molecule IP.
• Esketamine (intranasal) has the most durable and litigated IP posture, with Orange Book-listed delivery/formulation and depression regimen method-of-use claims shaping generic entry risk.
• Ketamine is largely exposed to generic competition at the molecule level, making commercial outcomes hinge on access, labeling, and contracted pricing rather than patent barriers.
• Memantine and dextromethorphan products are often defended through formulation, process, and extended-release or combination claims, which can delay copycats where the challenger cannot meet the same release and excipient profile.

---

FAQs

1. How do Orange Book “method of use” patents for NMDA antagonists change ANDA labeling requirements?
2. Which NMDA antagonist indications (depression vs Alzheimer’s) tend to have denser later-cycle method-of-use patent coverage?
3. What design-around strategies are most common for intranasal NMDA antagonists when delivery-system patents are asserted?
4. How does a Paragraph IV filing affect NMDA antagonist launch timing when multiple patents are listed per product?
5. What formulation characteristics most often determine non-infringement arguments for extended-release dextromethorphan products?

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Spravato (esketamine) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Ketamine hydrochloride prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Namenda (memantine) prescribing information.
4. U.S. Food and Drug Administration. (n.d.). Dextromethorphan-containing product labeling (NMDA-related indications, as applicable).
5. U.S. Food and Drug Administration. (n.d.). FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations; Hatch-Waxman framework resources.